Summary
Global
Markets Direct's, 'Psoriatic Arthritis - Pipeline Review, H1 2016', provides an
overview of the Psoriatic Arthritis pipeline landscape.
The
report provides comprehensive information on the therapeutics under development
for Psoriatic Arthritis, complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and molecule
type. The report also covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest news and
press releases. Additionally, the report provides an overview of key players
involved in therapeutic development for Psoriatic Arthritis and features
dormant and discontinued projects.
Global
Markets Direct's report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. The report is
built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries,
conferences, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources. Drug
profiles featured in the report undergoes periodic review following a stringent
set of processes to ensure that all the profiles are updated with the latest
set of information. Additionally, various dynamic tracking processes ensure
that the most recent developments are captured on a real time basis.
The
report helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
Note*: Certain
sections in the report may be removed or altered based on the availability and
relevance of data.
